Immunome, Inc. IMNM

NASDAQ | Biotech | Targeted oncology and antibody therapeutics

General analysis — not personal advice.

Signal

NEUTRAL

Sentiment

4/10

Risk

7/10

ASCO is now in the price and the market reaction has been negative on elevated volume, increasing the risk of continued volatility and weak technicals.

This picture changes. Follow Immunome, Inc. free — email when the signal or risk changes + a Sunday weekly brief.

Follow Immunome, Inc. free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Price & valuation

Last close

USD 25.69

2026-08-10

1 week

+0.7 %

3 months

+15.7 %

12 months

+159.2 %

From 52w high

-4.7 %

From 52w low

+185.8 %

Market sentiment

Sentiment has deteriorated materially as the stock broke to 52-week lows after ASCO, suggesting the market either “sold the news” or is reassessing probability/timing of regulatory outcomes and commercial potential despite supportive analyst commentary.

Why NEUTRAL?

ASCO is now in the price and the market reaction has been negative on elevated volume, increasing the risk of continued volatility and weak technicals. However, the core upside remains tied to regulatory milestones (FDA filing acceptance/review timeline and later decision), so the appropriate stance remains to review/resize exposure rather than aggressively averaging down or adding ahead of clearer signals.

Maintain a core position if already owned, but avoid aggressive adds ahead of FDA acceptance/ASCO; consider scaling exposure around catalysts based on risk budget.

We're already tracking Immunome, Inc. — here are the latest events we've registered

Recent News

Since 2026-06-03, Immunome has not released new clinical/regulatory updates or financing events. On June 4, 2026, the company reported inducement grants (353,000 options to 20 new hires, $20.78 strike, 4-year vesting). The stock remained weak into early June post-ASCO, with no clear new company-specific triggers.

Catalysts

FDA: NDA acceptance (varegacestat)

Dilution Risk

Assessment: Low

Create free account — follow 3 companies

What Firelda Watch includes for Immunome, Inc.

Add the company to your watchlist and get all of this automatically.

Free: 3 companies on your watchlist
Change history and monitoring for every company you follow
Sunday weekly brief — AI roundup of the week's news
Watch/Ultra: same-day email when something material happens

Want to see what a finished analysis looks like?

View a sample analysis

This is a real Firelda analysis. Your analysis of Immunome, Inc. will be delivered in the same format.

Own Immunome, Inc.? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.

Follow 3 companies free